Low dose cytosine arabinoside in the treatment of the primary myelodysplastic syndrome.
23 patients with primary myelodysplastic syndrome was observed in 1982-1988. 8 patients with RAEB and RAEB-t according to FAB criterias were treated with low dose cytosine arabinoside. No complete response and only one partial response +10 months duration was achieved. Treatment had a minor influence on the natural course of disease, and doesn't protect patients from the transformation into acute leukaemias.
Pluta
A
A
Department of Haematology, Medical Academy, Lublin, Poland.
Kowalewski
J
J
Kurowska
M
M
Spiewak
H
H
Hus
M
M
D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*
D003561:Cytarabine